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ABSTRACT
The most common neoplasm found in young to middle-aged men is testicular
cancer (TCa). This disease not only poses a risk of early death, but can also affect a
male's fertility and testosterone levels and can diminish one's mental health and/or
quality of life. One particular line of research that is emerging in the field is a possible
genetic association of TCa with female reproductive cancers. We employed a
systematic review to assess the methodological quality of articles that met the
inclusionary criteria. To be selected for this review, articles had to go through a primary,
secondary, and tertiary screening procedure using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. Four studies
were selected, and the Newcastle-Ottawa Scale (NOS) was used to measure the quality
of each nonrandomized, case-control or cohort study. Two articles received perfect
scores, one case-control study received a near-perfect score of 8 out of 9 stars, and
only one out of the four included studies received 5 out of 9 stars. Upon organizing and
analyzing the data, we found a significantly increased risk (20%) of female reproductive
cancer among women who had a father with TCa. Also, we found that men were 12%
more likely to develop TCa if they had a sister with female reproductive cancer, and
16% more likely if their mother had ovarian, endometrial, breast or cervical cancer. The
goal of this review was to assess the overall strength of association, or lack thereof,
between TCa and female reproductive cancers. Findings of this review suggest that an
association exists between these discordant forms of cancer. There were significant
risks found between mothers and sons, backed by substantial evidence of an X-linked
inheritance pattern. This information has the potential to improve our knowledge of
cancer etiology and treatment.
Keywords: testicular cancer, neoplasms, epidemiology, mortality, female reproductive,
ovarian, gonadal, familial association, genetic predisposition, inheritance

ii

ACKNOWLEDGMENTS

I would like to sincerely thank Dr. Michael Rovito and Dr. Eunkyung Lee for
their dedication to this project. They are both incredibly caring,
hardworking, and talented mentors. I would not have been able to complete
this thesis without their devotion to higher education and their students.

I would also like to thank my family for inspiring and motivating me every
day to work towards my goals.

iii

TABLE OF CONTENTS
Introduction ......................................................................................................................... 1
Testicular Cancer Overview............................................................................................ 1
Potential Causal Factors ................................................................................................. 1
Female Reproductive Cancer Associations ................................................................... 2
Objectives ........................................................................................................................ 2
Research Question ......................................................................................................... 2
Review of Literature............................................................................................................ 3
Testicular Cancer Overview............................................................................................ 3
Epidemiology and Prevalence ........................................................................................ 3
Etiology and Risk Associations ....................................................................................... 4
Female Reproductive Links ............................................................................................ 4
Methods .............................................................................................................................. 6
Study Design ................................................................................................................... 6
Data Reference and Search Strategy ............................................................................ 6
Study Selection ............................................................................................................... 6
Inclusion and Exclusion Criteria .................................................................................. 6
Screening Procedure ...................................................................................................... 7
Primary Screening ....................................................................................................... 7
Secondary Screening .................................................................................................. 7
Tertiary Screening ....................................................................................................... 8
Data Extraction and Methodological Quality Assessment ............................................. 8
Overview ...................................................................................................................... 8
Data Extraction and Quality......................................................................................... 8
Results ................................................................................................................................ 9
Publications Identified ..................................................................................................... 9
Search Strategy ........................................................................................................... 9
Search Results............................................................................................................. 9
Included ......................................................................................................................... 10
Eligibility......................................................................................................................... 10
iv

Screening ...................................................................................................................... 10
Identification .................................................................................................................. 10
Included Studies ............................................................................................................ 11
Discussion......................................................................................................................... 15
Summary ....................................................................................................................... 15
Systematic Review Findings ......................................................................................... 15
Key Findings .................................................................................................................. 18
Strengths and Limitations ............................................................................................. 21
Conclusion ..................................................................................................................... 21
References........................................................................................................................ 22

iv

LIST OF TABLES
Table 1…………………………………………………………………………..13
Table 2…………………………………………………………………………..14
Table 3…………………………………………………………………………..17
Table 4…………………………………………………………………………..17

LIST OF FIGURES
Figure 1…………………………………………………………………………..10
Figure 2…………………………………………………………………………..19
Figure 3…………………………………………………………………………..19
Figure 4…………………………………………………………………………..20
Figure 5…………………………………………………………………………..20

v

Introduction

Testicular Cancer Overview
Testicular cancer (TCa) is defined as a malignancy that develops in the tissue of
one or both testes (National Cancer Institute, 2019). TCa is a relatively rarer cancer
throughout the world but is the most common neoplasm in men aged 14 to 44 (Cheng et
al., 2018). The most common type of testicular malignancy is known as testicular germ
cell tumors (TGCT), caused by a neoplasm derived from germ cells (McGlynn et al.,
2010).
Over the last 40 years, the incidence of TCa has been increasing at a steady
rate, primarily among Caucasian males (Park et al., 2018). Currently, TCa accounts for
roughly 1-1.5% of all cancers in the global male population, and is the most common
malignancy in young adult men aged 20-40 years old (Boccellino et al., 2017).

Potential Causal Factors
Family history is the greatest risk factor for developing TCa, possibly due to
shared environmental exposure, or an X-linked/autosomal recessive genetic trait (Pyle
et al., 2016). A few other causal factors of TCa are cryptorchidism, premature birth, low
birth weight, and twinning (Smith et al., 2018). It is also possible that women with high
estrogen levels during gestation may be at risk of having sons with TCa (Piltoft et al.,
2017).
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Female Reproductive Cancer Associations
Research suggests that TCa may be the result of X-linked inheritance, with a
genetic susceptibility trait located near an ovarian cancer susceptibility trait on the Xchromosome (Etter et al., 2018). In a recent study, the researchers at the Roswell Park
Cancer Institute (2018) discovered an association between TCa and familial ovarian
cancer by analyzing data from an ovarian cancer registry. By examining the medical
histories of 34 males with a prior TCa diagnosis, these men were more likely to have a
mother or sister with familial ovarian cancer, compared to males with other cancer types
(Etter et al., 2018). Another study suggests that, although rare, there are familial
associations between female breast cancer and TCa (Zheng et al., 2017).

Objectives
To the authors' knowledge, however, no systematic review of literature exists that
examines the association between TCa and female reproductive cancers. The goal of
this systematic review, therefore, was to determine the methodological quality of studies
aiming to demonstrate the possible associations between TCa and female reproductive
cancers. Future directions and recommendations will be offered to guide future studies
in this specific line of research.

Research Question
Does an association exist between TCa and the various forms of female
reproductive cancers?
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Review of Literature

Testicular Cancer Overview
Testicular cancer (TCa) is a rare malignancy but most prevalent among men of
European descent, typically aged 15 to 44 (Znaor et al., 2020). Specifically,
Scandinavian men have rates of testicular cancer 5 to 10 times greater than those of
Asian and African ancestry (McGlynn et al., 2010).
According to one article, “There has been an increase in the incidence of
testicular cancer in many Western countries over the past 40 years and the global
incidence of testicular cancer has doubled over the past three decades” (Manecksha &
Fitzpatrick, 2009). Epidemiology of testicular cancer. BJU international, 104(9b), 13291333. Specifically, between 1973 and 2002, white American men experienced a 52%
increase in the incidence of TCa (Chia et al., 2010). Additionally, research shows that
Eastern Europe is predicted to see a 32% increase in TCa cases between 2010 and
2035 (Znaor et al., 2020).

Epidemiology and Prevalence
In 2020, there were an estimated 9,610 new cases of TCa, with 440 estimated
deaths in the United States alone (American Cancer Society, 2020). In addition, the
incidence among U.S. men rose by roughly 19% from 1992 (5.7 per 100,000) to 2009
(6.8 per 100,000) (Nigam et al., 2015). Luckily, medical advancements have improved
the 5-year survival rate of TCa to 97% from 2005 to 2011 (Siegel et al., 2016).
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However, the incidence of TGCT in Maori men of New Zealand is much more
prevalent. In 2002, Maori men had 10.6 cases per 100,000, in contrast to non-Maori
men who had significantly less cases, with 3.5 per 100,000 (New Zealand Health
Information Service 2006).

Etiology and Risk Associations
Testicular germ cell tumors (TGCT) are believed to develop from intratubular
germ cell neoplasia (IGCN), commonly known as carcinoma in situ (CIS) (Batool et al.,
2019). Roughly 98% of all TGCTs develop from germ cells, with more than half being
seminomas (55%), while the remaining are nonseminomas (44%) and spermatocytic
seminomas (1%) (McGlynn et al., 2010).
Pre-existing medical conditions seem to pose a risk of TGCT development in
addition to race/ethnicity (McGlynn et al., 2010). Cryptorchidism, commonly known as
undescended testicle(s), is the disorder most closely related to the formation of
testicular cancer (Smith et al., 2018). Patients diagnosed with cryptorchidism are about
4.3 times more likely to develop TGCT than patients without (Cook et al., 2010). While
there is no definitive relationship, research shows that there may be genetic
components that increase the likelihood of developing TCa among brothers and sons of
affected individuals (Batool et al., 2019).

Female Reproductive Links
Family history of TCa is a risk factor for developing TCa (Smith et al., 2018).
However, it is unknown if female reproductive cancers are a risk factor for testicular
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cancer in males. Etter and colleagues (2018) state that there is “evidence for several
susceptibility genes, including 27 identified autosomal loci and a putative X-linked gene
at Xq27, TGCT1” (p. 184). This indicates a possible familial association between male
and female genitourinary tract anomalies.
In the past three decades, research has been conducted with results linking TCa
to the X-chromosome (Looijenga et al., 1997). This is significant because human males
normally have one X chromosome and one Y chromosome, obtaining one sex
chromosome from each parent. Therefore, male offspring will receive their X
chromosome from the mother, and their Y chromosome from the father.
Interestingly enough, Eng and colleagues (2018) identified that this X-linked
testicular cancer susceptibility gene is located in close proximity to an ovarian cancer
susceptibility gene (Eng et al., 2018). This further proves that these recognized familial
germ cell neoplasms are driven by this X-linked gene.
Giambartolomei and colleagues, “found evidence of familial [ovarian germ cell
tumor] clustering, both site-specific and in combination with TGCT, and noted distinct
histologic patterns for ovarian germ cell tumors (OGCT) and TGCT, by age.”
(Giambartolomei et al., 2009, pg. 5). They claim this supports the theory that ovarian
germ cell tumors may be a rare manifestation of familial gonadal tumor syndrome.
Another study by Zheng and colleagues (2017) suggests, albeit rare, familial
associations may be present between female breast cancer and TCa.
This accumulating evidence implies that associations between TCa and female
reproductive cancers may exist. Further investigation is needed to discover definitive
manifestations of familial gonadal tumor syndrome.
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Methods

Study Design
A systematic review was employed to assess the methodological quality of
qualified articles to assess the strength of association between the manifestation of TCa
and a family history of female reproductive cancers. Each article was analyzed using
the Newcastle-Ottawa Scale (NOS) to measure the quality of each study. Sources were
screened and selected by following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement guidelines (Liberati et al. 2009).

Data Reference and Search Strategy
The Medical Subject Headings (MeSH) database was used to index articles and
develop keywords to search pertinent literature. The Cumulative Index to Nursing and
Allied Health Literature (CINAHL; 1990 to present), PubMed (1990 to present),
ProQuest (1990 to present), and Google Scholar (1990 to present) databases were
used to find literature relevant to this study. Keywords used to search literature included
variants of testicular cancer, neoplasms, epidemiology, mortality, female reproductive,
ovarian, gonadal, familial association, genetic predisposition, and inheritance.

Study Selection

Inclusion and Exclusion Criteria
Studies were required to meet the following inclusionary criteria to be evaluated
in the systematic review and assessed using the NOS. Only peer-reviewed, scholarly
6

articles were included in the screening process. Articles had to be epidemiologicallyfocused analytical studies showing associations between testicular cancer and female
reproductive cancers in order to be accepted.
Genetically-focused articles that focus solely on the pathophysiological
processes of TCa were excluded from the systematic review. Furthermore, drug
patents, medical procedures, case studies, review papers, and interventions were also
rejected. Non-peer reviewed articles were excluded from the screening procedure.

Screening Procedure
The PRISMA flow diagram was used to organize the flow of selection of studies
while screening peer-reviewed journals. This tool was used to map out the number of
studies included or excluded in each primary, secondary, and tertiary screening stage.
The qualifying studies were assessed using the following screening guidelines:

Primary Screening
First, titles and abstracts were screened based upon their relevance to the study
objectives. Any articles showing an association between testicular cancer and other
cancers were kept for further screening. Non-peer reviewed articles and unpublished
materials were excluded.

Secondary Screening
Then, full articles were screened for relevance. Articles showing a link between
testicular cancer and the main types of female reproductive cancer were kept for further
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screening. Female reproductive cancers are inclusive of cervical, ovarian, uterine,
endometrium, vaginal, vulvar, and breast cancer (Mun et al., 2015).

Tertiary Screening
Last, articles that showed definitive evidence of an association between TCa and
female reproductive cancer were kept for the data extraction. These articles were then
assessed using the NOS.

Data Extraction and Methodological Quality Assessment

Overview
The articles deemed relevant were scored using the NOS, to measure the quality
of nonrandomized studies, including, but not limited to, case-control and cohort studies.

Data Extraction and Quality
The information collected from each study included study design, number of
human subjects, confounding variables and method of control. Additional information
consisted of TCa characteristics identified, which female reproductive cancers were
investigated, and results and data. The results were summarized by utilizing an oddsratio and confidence interval. The NOS assessed the methodological quality of cohort
and case-control studies with nine evaluation items on the adequacy of the
recruitment/selection process of study participants (4 items), comparability of
comparison groups (2 items), and exposure/outcome ascertainment (3 items).
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Results

Publications Identified

Search Strategy
Multiple searches were conducted using the Cumulative Index to Nursing and
Allied Health Literature (CINAHL; 1990 to present), PubMed (1990 to present),
ProQuest (1990 to present), and Google Scholar (1990 to present) databases using the
keywords testicular cancer, neoplasms, epidemiology, mortality, female reproductive,
ovarian, gonadal, familial association, genetic predisposition, and inheritance.

Search Results
These searches returned approximately 3,780 results (Figure 1). Once the
duplicates were removed, there were 3,402 records remaining. Any patents, clinical
trials, or other studies that did not have a cohort or case-control study design were
rejected (n = 2,374). Next, titles and abstracts were screened based upon their
relevance to the thesis, while non-peer reviewed articles and unpublished materials
were excluded (n = 786). Any articles showing an association between TCa and other
cancers were kept for secondary screening. Of the remaining 242 records, full articles
were screened for relevance. Articles that displayed an association between TCa and
the main types of female reproductive cancer (cervical, ovarian, uterine, vaginal, vulvar,
and breast cancer) were kept for tertiary screening (n = 12). Last, articles that showed
definitive evidence of an association between TCa and female reproductive cancer were
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kept for the systematic review (n = 4). These articles were then assessed using the

Eligibility

Screening

Identification

NOS quality assessment tool.

Additional records identified
through other sources
(n = 0)

Records identified through
database searching
(n = 3,780)

Records after duplicates removed
(n = 3,402)

Records screened
(n = 1,028)

Records excluded
(n = 786)

Full-text articles assessed
for eligibility
(n = 242)

Full-text articles excluded,
with reasons
(n = 230)
(patents, clinical trials, and
irrelevant studies
excluded)

Included

Studies included in
qualitative synthesis
(n = 12)

Studies included in
quantitative synthesis
(systematic review)
(n = 4)

Figure 1. PRISMA Flow Diagram.
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Included Studies
There were four studies that met the eligibility requirements for the systematic
review (Table 1). This was inclusive of two cohort studies (Zheng et al., 2017; Hemminki
et al., 2005), and two case-control studies (Etter et al., 2018; Nordsborg et al., 2011).
Each study was evaluated using the NOS scale. Three out of the four studies (Zheng et
al., 2017; Hemminki et al., 2005; Nordsborg et al., 2011) achieved a good quality score.
There was only study (Etter et al., 2018) that received an acceptable quality score of 5
out of 9 stars.
The measures of association were depicted in an estimated hereditary risk table
(Table 2). This table illustrates the estimated risk of a first-degree relative with either
TCa or female reproductive cancer. The data is organized as two groups of hereditary
directionalities (male to female; female to male), separated into five subgroups (father to
daughter; brother to sister; son to mother; sister to brother; mother to son). For
example, the risk ratio of female breast cancer was 1.14 (95% CI 1.00-1.30) for women
who had a father with TCa. The estimated risk of each hereditary directionality was then
calculated by meta-analysis using random effects models averaging the ratios
associated with their corresponding subgroup.
The average estimated risk (shown in Table 2) of female reproductive cancer
was found to be 20% higher in women who had a father with TCa. Women who had a
brother with TCa were only 1% more likely to develop female reproductive cancer.
There was no significant association found between women with female reproductive
cancer who had sons with TCa. Men who had a sister with female reproductive cancer
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were 12% more likely to develop TCa, and 16% more likely if they had a mother with
ovary, endometrium, breast or cervix cancer.
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Table 1. Study summaries of 4 articles included in systematic review.
Author Name(s)

Etter

Nordsborg

Zheng

Hemminki

Date

2018

2011

2017

2005

Study Design

Familial case-control

Population-based case-control
study

Cohort

Cohort

Region of Study

USA

Denmark

Sweden

Sweden

Number of Participants

2,636 families with multiple
cases of ovarian cancer

9,891

76,060 female offspring with
BC (12266 families)

175,635 off springs

Data source

Familial Ovarian Cancer
Registry

Danish Cancer Registry for
cases and Danish Civil
Registration System for
controls

Swedish Family-Cancer
Database

Swedish Family-Cancer
Database

Median 35 (0-96)

0-70

0-70

Familial cancer risk in
offspring/FDR in two ways

Familial cancer risk in
offspring/FDR in two ways

Age (years)
Cases

34 men with testicular cancer

3,297 with testicular cancer

Controls

2,894 men with non-testicular
cancer

6,594 matched controls

Exposure

First-degree relatives (FDR)
with ovarian cancer

First-degree relatives with
other cancers

Outcome
Follow-up Period

1958-2002

Incidence

4,586 TC in sons and 4315 in
fathers

Confounder Included in
Study
Quality Score

None - univariate logistic
regression
5

Number of relatives
8

Age group, sex, calendar
period, residential area, and
SES
9
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Age, sex, tumor type, period,
ses, residential area
9

Table 2. Measures of association of the estimated hereditary risk.
Male to female

Hereditary
Directionality

Risk Ratio

Father’s with TCa
daughter’s with female
reproductive cancer

Female to male

Brother’s with TCa
sister’s with female
reproductive cancer

Sons with TCa
mother’s with female
reproductive cancer

RR for breast cancer =
1.06 (0.86-1.31) when
any FDR* had TCa

RR for breast cancer =
1.14 (1.00-1.30) when
brother had TCa

RR for breast cancer =
1.06 (0.86-1.31) when
any FDR* had TCa

RR for TCa = 1.66 (0.873.15) when sister had
ovary cancer

RR for TCa = 3.32 (1.467.55) when mother had
ovary cancer

RR for female genital
organ cancer = 0.89
(0.68-1.16) when any
FDR* had TCa

RR for breast cancer =
0.90 (0.66-1.22) when
brother had TCa

RR for female genital
organ cancer = 0.89
(0.68-1.16) when any
FDR* had TCa

RR for TCa = 1.14 (1.061.23) when sister had
breast cancer

RR for TCa = 1.14 (1.061.23) when mother had
breast cancer

RR for breast cancer =
1.14 (1.00-1.30) when
father had TCa

RR for cervix cancer =
1.68 (0.87-3.24) when
brother had TCa

RR for TCa = 0.98 (0.631.52) when sister had
breast cancer

RR for TCa = 1.17 (0.981.39) when mother had
breast cancer

RR for breast cancer =
1.28 (0.85-1.92) when
father had TCa

RR for endometrium
cancer = 1.09 (0.502.38) when brother had
TCa

RR for TCa = 0.80 (0.312.07) when sister had
cervix cancer

RR for TCa = 0.74 (0.441.25) when mother had
cervix cancer

RR for cervix cancer =
0.69 (0.19-2.54) when
father had TCa

RR for ovary cancer =
0.97 (0.44-2.14) when
brother had TCa

RR for TCa = 1.34 (0.453.98) when sister had
endometrium cancer

RR for TCa = 1.05 (0.701.57) when mother had
endometrium cancer

RR for TCa = 1.11 (0.432.88) when sister had
ovary cancer

RR for TCa = 1.14 (0.761.71) when mother had
ovary cancer

1.12

1.16

RR for endometrium
cancer = 1.52 (0.514.49) when father had
TCa

Sister’s with female
reproductive cancer
brother with TCa

Mother’s with female
reproductive cancer
son’s with TCa

RR for ovary cancer =
0.75 (0.20-2.75) when
father had TCa
Average
Estimated
Risk

1.20

1.01

--

*FDR = first-degree relative
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Discussion

Summary
The Newcastle-Ottawa assessment scale is well-known for determining the
quality scores of articles and assessing the risk of bias. A ‘star-system’ is utilized to
measure the quality of cohort and case-control studies. This systematic review preferred
the NOS tool, in order to measure the quality of articles that showed an association
between TCa and female reproductive cancers. Each article that passed the tertiary
screening process was analyzed using the NOS to measure the quality of
nonrandomized study. This quality assessment tool utilizes a ‘star system’ to evaluate
the study group selection, comparability, and ascertainment of the exposure or outcome
of interest.

Systematic Review Findings
A total of four studies were eligible for use in the systematic review (Zheng et al.,
2017; Hemminki et al., 2005, Etter et al., 2018; Nordsborg et al., 2011). Church and
colleagues deliberated in order to agree upon a score for each selected study. Two
articles (Zheng et al., 2017; Hemminki et al., 2005) received perfect scores (shown in
Table 3) according to the NOS requirements. In other words, these two studies
contained quality selection of groups, comparability, and ascertainment of outcomes.
This signifies that both of these studies were of good quality. One case-control study
(Nordsborg et al., 2011) received a near-perfect score of 8 out of 9 stars, due to the lack
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of non-response rate provided (Table 4). However, this is still considered to be a study
of good quality. Only one out of the four included studies (Etter et al., 2018) was found
to be of acceptable quality. This conclusion was met due to a lack of comparability,
ascertainment of exposure, and non-response rate (Table 4).
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Table 3. Methodological quality assessment of cohort studies included in the systematic review.

Table 4. Methodological quality assessment of case-control studies included in the systematic review.
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Key Findings
Upon calculating the average estimated risk for each subgroup (shown in Table
2), we can infer that males are 16% more likely to develop TCa when their mother has
female reproductive cancer (inclusive of ovarian, breast, cervix and endometrial
cancer). This may be due to a probable X-linked trait passed from mother to son. As
previously stated, one study identified an X-linked TCa susceptibility gene in close
proximity to an ovarian cancer susceptibility gene (Eng et al., 2018). This further proves
that an association exists between TCa and female reproductive cancer.
By compiling the available data into forest plots (Figures 2 through 5), the risk of
discordant cancer inheritance was concluded. The hereditary risk of developing TCa
was found to be 14% higher among men who had a mother or sister with female
reproductive cancer (shown in Figure 2 and Figure 4).
Additionally, the limited number of eligible studies may not fully reflect each
individual risk. For example, the risk of female reproductive cancer was merely 8%
higher in women with a father or brother that had TCa (shown in Figure 3 and Figure 5).
However, because evidence is sparse, this may actually indicate a clinically significant
risk factor.
There are other variables that must be considered. Mother’s and son’s may be
more likely to both develop these forms of cancer due to shared behavioral or
environmental factors.

18
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Strengths and Limitations
This systematic review was not without its own limitations. It proved challenging
to find articles that met the eligibility requirements. To the authors knowledge, there is
no other systematic review of literature that examines the association between TCa and
female reproductive cancers. This is still a novel and developing field of study, so there
is a very limited amount of epidemiological analytical studies focused on the
associations between these discordant cancers. More studies must be conducted to
achieve more accurate results.

Conclusion
The purpose of this study was to determine the methodological quality of
nonrandomized studies showing any possible associations between TCa and female
reproductive cancer. Findings of this review suggest that an association exists between
these discordant cancers. There were significant risks found between mothers and
sons, backed by substantial evidence of an X-linked inheritance pattern. We hope to
bring attention to this field of study so that more definitive evidence may be derived.
This developing topic has the potential to improve our knowledge of cancer etiology and
treatment.
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